IL33 and allergic disease: Despite the current lack of research on using etokimab for AR treatment, considering the central role of IL-33 in the pathogenesis of allergic diseases and the significant efficacy of anti-IL-33 biologics like etokimab in various allergic conditions, such monoclonal antibodies hold great potential for application in AR treatment.